NADCIŚNIENIE PŁUCNE — PATOFIZJOLOGIA I LEKI WYKORZYSTYWANE W TERAPII

Iwona Lewandowska Lewandowska; Monika Zielińska-Pisklak; Łukasz Szeleszczuk; Dariusz Maciej Pisklak; Marcin Sobczak

doi:10.56782/pps.17

Published : 2020-08-07

Vol. 18 No. 2 (2020)

PULMONARY HYPERTENSION — PATHOPHYSIOLOGY AND DRUGS USED IN THERAPY

Iwona Lewandowska Lewandowska

Monika Zielińska-Pisklak

Łukasz Szeleszczuk

Dariusz Maciej Pisklak

Marcin Sobczak

DOI: https://doi.org/10.56782/pps.17

Abstract

Pulmonary hypertension (PH) is a relatively rare disease with a severe course characterized by the presence of elevated blood pressure in the pulmonary circulation. Non-specific symptoms and the lack of a simple diagnostic method contribute to the late detection of the disease, which significantly worsens the prognosis and increases the cost and invasiveness of treatment. In this article a classification of PH due to its etiology is presented and the individual types of PH with regard to their pathophysiology are characterized. Moreover, PH diagnostics and drug types used in therapy (e.g. endothelin receptor antagonists, prostanoids, phosphodiesterase type 5 inhibitors) are described.

Keywords:

pulmonary hypertension, phosphodiesterase type 5 inhibitors, endothelin receptor antagonists, prostanoids

Similar Articles

Emilia Sokołowska, Andrzej Mogielnicki, SEARCH FOR PROTAMINE REPLACEMENTS: EFFICACIOUS AND SAFE INHIBITION OF BLEEDING INDUCED BY PARENTERAL ANTICOAGULANTS , Prospects in Pharmaceutical Sciences: Vol. 14 No. 2 (2016)
Agnieszka Lis-Cieplak, ADAMANTANE DERIVATIVES - VARIETY OF BIOLOGICAL ACTIVITIES. A REVIEW OF MEDICATIONS APPROVED IN POLAND AND POTENTIAL DRUGS , Prospects in Pharmaceutical Sciences: Vol. 10 No. 3 (2012)

<< < 1 2 3 4 5

You may also start an advanced similarity search for this article.

Details

References

Statistics

Authors

Download files

PDF (Język Polski)

Citation rules

Lewandowska, I. L., Zielińska-Pisklak, M., Szeleszczuk, Łukasz, Maciej Pisklak, D., & Sobczak, M. (2020). PULMONARY HYPERTENSION — PATHOPHYSIOLOGY AND DRUGS USED IN THERAPY. Prospects in Pharmaceutical Sciences, 18(2), 10–18. https://doi.org/10.56782/pps.17

Altmetric indicators

Cited by / Share

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

Bhogal S., Mukherjee D. et al., Current Trends and Future Perspectives in the Treatment of Pulmonary Arterial Hypertension,Current Problems in Cardiology, 2018, 43(5), 191-216. DOI: https://doi.org/10.1016/j.cpcardiol.2017.10.002

Hoeper M., Marius M. et al., Definitions and Diagnosis of Pulmonary Hypertension, Journal of the American College of Cardiology, 2013, 62(25), 42-50. DOI: https://doi.org/10.1016/j.jacc.2013.10.032

Galiè N., Simmoneau G., The Fifth World Symposium on Pulmonary Hypertension, Journal of the American College of Cardiology, 2013, 62(25), 1-3. DOI: https://doi.org/10.1016/j.jacc.2013.10.030

Simonneau G., Robins I. et al.,Updated Clinical Classification of Pulmonary Hypertension, Journal of the American College of Cardiology, 2013, 62(25), 34-41. DOI: https://doi.org/10.1016/j.jacc.2013.10.029

Barst R., Rubin L., Pulmonary Hypertension, w Fuster V., Walsh R., Harrington R., eds. Hurst’s The Heart, New York, 2011.

Bhogal S., Mukherjee D. et al., Current Trends and Future Perspectives in the Treatment of Pulmonary Hypertension: WHO Group II-V, Current Problems in Cardiology, 2018, 43(5), 217-231. DOI: https://doi.org/10.1016/j.cpcardiol.2017.10.003

Vachiéry J.-L., Yochai A. et al., Pulmonary Hypertension Due to Left Heart Diseases, Journal of the American College of Cardiology, 2013, 62(25), 100-108. DOI: https://doi.org/10.1016/j.jacc.2013.10.033

Seeger W., Yochai A. et al., Pulmonary Hypertension in Chronic Lung Diseases, Journal of the American College of Cardiology, 2013, 62(25), 109-105. DOI: https://doi.org/10.1016/j.jacc.2013.10.036

Wrobel J., Thompson B. et al., Mechanisms of pulmonary hypertension in chronic obstructive pulmonary disease: A pathophysiologic review, Journal of Heart and Lung Transplantation, 2012, 31(6), 557-564. DOI: https://doi.org/10.1016/j.healun.2012.02.029

Payares-Jardim C., Diagnóstico y tratamiento de la hipertensión pulmonar tromboembólica crónica, Revista Colombiana de Cardiología, 2017, 24(1), 48-54. DOI: https://doi.org/10.1016/j.rccar.2017.08.008

Weatherald, J., Savale, L. & Humbert, M. Medical Management of Pulmonary Hypertension with Unclear and/or Multifactorial Mechanisms (Group 5): Is There a Role for Pulmonary Arterial Hypertension Medications?. Current Hypertension Report, 2017, 19(86) DOI: https://doi.org/10.1007/s11906-017-0783-5

Kopeć G., Podolec P., Poradnik dla Pacjentów Tętnicze Nadciśnienie Płucne. Diagnostyka i leczenie, 2016, wyd. I, Warszawa 2016.

Wieteska M., Wszystko o Tętniczym Nadciśnienie Płucnym Informator dla Pacjentów, wyd. III, Warszawa 2015.

Galiè N., Humbert M. et al., Wytyczne ESC/ERS dotyczące rozpoznawania i leczenia nadciśnienia płucnego w 2015 roku, Kardiologia Polska, 2015, 73, 1127-1206.

Oki Y., Kaneko M. et al., Usefulness of the 6-minute walk test as a screening test for pulmonary arterial enlargement in COPD, International Journal of COPD, 2016, 11, 2869-2875. DOI: https://doi.org/10.2147/COPD.S114497

Jasińska-Stroschein M., Orszulak-Michalak D., Nowe strategie w farmakoterapii tętniczego nadciśnienia płucnego, Postępy Higieny i Medycyny Doświadczalnej, 2017, 71, 577-588. DOI: https://doi.org/10.5604/01.3001.0010.3838

Greenberg B., Novel Therapies for Heart Failure – Where do They Stand?, Circulation Journal, 2016, 80, 1882-1891. DOI: https://doi.org/10.1253/circj.CJ-16-0742

Tantini B., Manes A. et al., Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells, Basic Research in Cardiology, 2005, 100(2), 131-138. DOI: https://doi.org/10.1007/s00395-004-0504-5

Grady D., Weiss M. et al., Medication and patient factors associated with adherence to pulmonary hypertension targeted therapies, Pulmonary Circulation, 2011, 8(1), 1-9. DOI: https://doi.org/10.1177/2045893217743616

Mittra R., Mieler W., Chapter 89 – Drug Toxicity of the Posterior Segment, Retina (Fifth Edition), 2013, 2, 1532-1554. DOI: https://doi.org/10.1016/B978-1-4557-0737-9.00089-8

Hyland R., Roe E. G. H. et al., Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil, British Journal of Clinical Pharmacology, 2001, 51(3), 239-248. DOI: https://doi.org/10.1046/j.1365-2125.2001.00318.x

Forgue S. T., Patterson B. E. et al., Tadalafil pharmacokinetics in healthy subjects, British Journal of Clinical Pharmacology, 2006, 61(3), 280-288. DOI: https://doi.org/10.1111/j.1365-2125.2005.02553.x

Hoette S., Jardim C., de Souza R., Diagnosis and treatment of pulmonary hypertension: an update, Journal Brasileiro Pneumologia, 2010, 36, 795-811. DOI: https://doi.org/10.1590/S1806-37132010000600018

Mubarak K., A review of prostaglandinanalogs in the management of patients with pulmonary arterial hypertension, Respiratory Medicine, 2010, 104(1), 9-21. DOI: https://doi.org/10.1016/j.rmed.2009.07.015

Hardin E. A., Chin K. M., Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy, Drug Design, Development and Therapy, 2016, 10, 3747-3754. DOI: https://doi.org/10.2147/DDDT.S103534

Torres F., Farber H. et al., Efficacy and safety of ralinepag, a noveloral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebocontrolled trial, European Respiratory Journal, 2019, 54(4), 1-11. DOI: https://doi.org/10.1183/13993003.01030-2019

Galiè N., Corris P. et al., Updated Treatment Algorithm of Pulmonary Arterial Hypertension, Journal of the American College of Cardiology, 2013, 62(25), 60-72. DOI: https://doi.org/10.1016/j.jacc.2013.10.031

Hoeper M.M., Barst R.J. et al., Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study, Circulation, 2013, 127, 1128-1138. DOI: https://doi.org/10.1161/CIRCULATIONAHA.112.000765

Gomberg-Maitland M., Bull T.M., et al., New trial designs and potential therapies for pulmonary artery hypertension. Journal of the American College of Cardiology, 2013, 62(25), D82-D91. DOI: https://doi.org/10.1016/j.jacc.2013.10.026

Vachiéry J.-L., Yochai A. et al., Pulmonary hypertension due to left heart disease, Journal

Ghofrani H.A., D'Armini A.M. et al., CHEST-1 Study Group Riociguat for the treatment of chronic thromboembolic pulmonary hypertension, New England Journal of Medicine, 2013, 369(4), 319-329 DOI: https://doi.org/10.1056/NEJMoa1209657

Simonneau G., D'Armini A.M. et al., Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2), European Respiratory Journal, 2015, 45(5), 1293-1302. DOI: https://doi.org/10.1183/09031936.00087114

Dertevelle P., Fadel E. et al., Chronic thromboembolic pulmonary hypertention, European Respiratory Journal, 2004, 23, 637-648. DOI: https://doi.org/10.1183/09031936.04.00079704

Iwona Lewandowska Lewandowska

Affiliation:

Studenckie Koło Naukowe „Spectrum” przy Katedrze Chemii Analitycznej i Biomateriałów, Wydział Farmaceutyczny z Oddziałem Medycyny Laboratoryjnej, Warszawski Uniwersytet Medyczny, ul. Banacha 1, 02-097 Warszawa; Studenckie Koło Naukowe „Free Radicals” przy Zakładzie Chemii Fizycznej, Wydział Farmaceutyczny z Oddziałem Medycyny Laboratoryjnej, Warszawski Uniwersytet Medyczny, ul. Banacha 1, 02-097 Warszawa Poland

Monika Zielińska-Pisklak

mpisklak@wum.edu.pl

Affiliation:

Zakład Chemii Biomateriałów, Katedra Chemii Analitycznej i Biomateriałów, Wydział Farmaceutyczny z Oddziałem Medycyny Laboratoryjnej, Warszawski Uniwersytet Medyczny, ul. Banacha 1, 02-097 Warszawa Poland

Łukasz Szeleszczuk

Affiliation:

Zakład Chemii Fizycznej, Katedra Farmacji Fizycznej i Bioanalizy, Wydział Farmaceutyczny z Oddziałem Medycyny Laboratoryjnej, Warszawski Uniwersytet Medyczny, ul. Banacha 1, 02-097 Warszawa Poland

Dariusz Maciej Pisklak

Affiliation:

Zakład Chemii Fizycznej, Katedra Farmacji Fizycznej i Bioanalizy, Wydział Farmaceutyczny z Oddziałem Medycyny Laboratoryjnej, Warszawski Uniwersytet Medyczny, ul. Banacha 1, 02-097 Warszawa Poland

Marcin Sobczak

Affiliation:

PULMONARY HYPERTENSION — PATHOPHYSIOLOGY AND DRUGS USED IN THERAPY

Iwona Lewandowska Lewandowska

Monika Zielińska-Pisklak

Łukasz Szeleszczuk

Dariusz Maciej Pisklak

Marcin Sobczak

Abstract

Keywords:

Most read articles by the same author(s)

Similar Articles

Iwona Lewandowska Lewandowska

Monika Zielińska-Pisklak

Łukasz Szeleszczuk

Dariusz Maciej Pisklak

Marcin Sobczak